血清中巨噬细胞移动抑制因子表达与大肠癌的分期及淋巴结转移相关性研究

目的研究大肠癌患者血清中巨噬细胞移动抑制因子（MIF）表达水平与临床特征的关系。方法利用酶联免疫吸附的方法（ELISA）检测75例大肠癌患者（35例原发性大肠癌及40例有淋巴结转移的大肠癌）及40例非癌对照人群血清中MIF的表达水平，探讨MIF与临床特征的关系。结果与正常人群血清中MIF表达水平相比（平均值13．6ng／ml），大肠癌患者血清中MIF表达水平明显增高（平均值31．2ng／ml），且表达水平增高与临床进展分期（P〈0．05）及淋巴结转移相关（P〈O．05）。结论MIF在血清中表达增高可能促进了大肠癌的发病过程，并与大肠癌的分期及淋巴结转移密切相关。

The relation of MIF level in serum and the stages and lymphnode metastasis in patients with colorectal cancer

Objective To study the relationship between serum macrophage migration inhibitory factor (MIF) levels and clinical features in the patients with colorectal cancer. Methods Enzyme-linked immunosorbent assays was used to detect the concentration of MIF in sera of 75 patients with colorectal cancer (35 case with primary colorectal cancer and 40 cases with lymphnode metastasis of colorectal cancer) and 40 healthy controls. The relationship between serum MIF levels and clinical features was analyzed. Results Serum MIF was found to be significantly elevated in the patients with colorectal cancer(mean value 31.2ng/ml) compared with healthy subjects (mean value 13.6ng/ml) (P <0. 001). The levels of MIF in colorectal cancer were significantly correlated with advanced clinical progression pathology stages (P <0. 05) and lymph node metastasis (P < 0. 05). Conclusions Increased expression level of MIF in serum may promote the pathogenesis of colorectal cancer and M1F is closely associated with the stages and lymph node metastasis of colorectal cancer.